Sam Brusco, Associate Editor07.18.22
Nihon Kohden OrangeMed has earned U.S. Food and Drug Administration (FDA) 510(k) clearance for its NKV-330 ventilator system.
The non-invasive ventilator offers respiratory support for both adult and pediatric patients. It also offers invasive ventilation and high flow oxygen therapy, as well as continuous CO2 monitoring when using the company’s cap-ONE NIV mask, an interface for quality monitoring directly from the ventilator.
“The NKV-330 ventilator can help hospitals who face a limited choice of new non-invasive ventilator platforms for adult and pediatric patients,” Eiichi Tanaka, president and CEO of Nihon Kohden America told the press. “This new platform offers a seamless transition between non-invasive therapy and high flow oxygen therapy to meet the changing needs of patients. The continuous monitoring of ETCO2, the excellent portability, dual HEPA filtration, ‘hot-swap’ battery, and many other features in the NKV-330 makes it a great choice for hospitals and healthcare providers.”
The system began shipping this month and has been available outside the U.S. since 2019.
The non-invasive ventilator offers respiratory support for both adult and pediatric patients. It also offers invasive ventilation and high flow oxygen therapy, as well as continuous CO2 monitoring when using the company’s cap-ONE NIV mask, an interface for quality monitoring directly from the ventilator.
“The NKV-330 ventilator can help hospitals who face a limited choice of new non-invasive ventilator platforms for adult and pediatric patients,” Eiichi Tanaka, president and CEO of Nihon Kohden America told the press. “This new platform offers a seamless transition between non-invasive therapy and high flow oxygen therapy to meet the changing needs of patients. The continuous monitoring of ETCO2, the excellent portability, dual HEPA filtration, ‘hot-swap’ battery, and many other features in the NKV-330 makes it a great choice for hospitals and healthcare providers.”
The system began shipping this month and has been available outside the U.S. since 2019.